219 related articles for article (PubMed ID: 21284066)
1. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
2. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S
Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039
[TBL] [Abstract][Full Text] [Related]
3. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
4. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
5. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
Gelenberg AJ; Dunner DL; Rothschild AJ; Pedersen R; Dorries KM; Ninan PT
J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
[TBL] [Abstract][Full Text] [Related]
6. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
[TBL] [Abstract][Full Text] [Related]
7. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
Gudayol-Ferré E; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P; Cruz D; Hernández S; Genis A; Carrillo-Guerrero MY; Avilés Reyes R; Guàrdia-Olmos J
J Affect Disord; 2010 Dec; 127(1-3):343-51. PubMed ID: 20584552
[TBL] [Abstract][Full Text] [Related]
8. Problem-solving ability and comorbid personality disorders in depressed outpatients.
Harley R; Petersen T; Scalia M; Papakostas GI; Farabaugh A; Fava M
Depress Anxiety; 2006; 23(8):496-501. PubMed ID: 16845662
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression.
Pedrelli P; Feldman GC; Vorono S; Fava M; Petersen T
Psychiatry Res; 2008 Dec; 161(3):302-8. PubMed ID: 18976817
[TBL] [Abstract][Full Text] [Related]
10. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
Psychiatry Clin Neurosci; 2011 Aug; 65(5):510-7. PubMed ID: 21851460
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL
J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
[TBL] [Abstract][Full Text] [Related]
12. [Depressions: current concepts].
Corruble E
Encephale; 2010 Dec; 36 Suppl 5():S104-7. PubMed ID: 21211627
[TBL] [Abstract][Full Text] [Related]
13. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
Nierenberg AA; Pava JA; Clancy K; Rosenbaum JF; Fava M
Biol Psychiatry; 1996 Oct; 40(8):691-6. PubMed ID: 8894060
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
16. The impact of medical comorbidity on acute treatment in major depressive disorder.
Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
[TBL] [Abstract][Full Text] [Related]
17. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
[TBL] [Abstract][Full Text] [Related]
19. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
Nierenberg AA; Husain MM; Trivedi MH; Fava M; Warden D; Wisniewski SR; Miyahara S; Rush AJ
Psychol Med; 2010 Jan; 40(1):41-50. PubMed ID: 19460188
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
